rg002c0106
Nucleic acidexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Aug 9, 2024 (NCT06494527)
Timeline
Mechanism of action
- Complement C3ANTISENSE INHIBITOR
C3 antisense inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07305974 | Phase 2 | Sep 8, 2025 | Rigerna Therapeutics |
| NCT06494527 | Phase 1 | Aug 9, 2024 | Government of China |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Government of China | Government | 1 | 1 | 1 | 2024 |
| Rigerna Therapeutics | For profit | 1 | 1 | 1 | 2025 |
2 organizations
Page 1 / 1